Trials / Recruiting
RecruitingNCT06974929
A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer
An Open-Label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 Combination Therapy in Patients With Breast Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-6209 Capsules | Oral HRS-6209 capsules. |
| DRUG | Letrozole Tablets | Oral Letrozole tablets. |
| DRUG | HRS-2189 Tablets | HRS-2189 tablets. |
Timeline
- Start date
- 2025-05-22
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2025-05-16
- Last updated
- 2025-12-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06974929. Inclusion in this directory is not an endorsement.